Biotherapeutics News: Breaking Biotherapeutics News, Comments and Articles.

Alnylam to Webcast Presentation at Deutsche Bank 38th Annual dbAccess Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Wednesday, May 29, 2013 at 2:50 p.m. ET at The Westin Boston Waterfront Hotel in Boston. A live audio webcast of the presentati...

Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer

- Expertise in the development of numerous commercialized drugs and his military background to support Company’s development path - Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), today announced Col. (ret.) Charles L. Pamplin III, M.D., was appointed to the position of Chief Medical Officer effective May 20. In this position, he reports...

Download Presentation: Exploiting the modularity of domain antibodies to advance biotherapeutic platforms

Developing therapeutic monoclonal antibodies and ADC’s is a key focus of the pharmaceutical industry’s R&D. The European Antibody Congress 2012 bought together senior level executives [...]

Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer

SAN FRANCISCO, CA -- (Marketwired) -- 05/21/13 -- Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that it completed enrollment of 120 patients in the TRAVERSE study, a global randomized Phase 2b clinical trial evaluating the efficac...

MaxCyte Presents Unprecedented Data Using Flow Electroporation for CHO-Based Transient Gene Expression to Achieve Gram Scale Antibody Production and Rapid Stable Cell Line Generation

Transient Gene Expression (TGE) Method Reporting Over 1 Gram/Liter Antibody Titers to be Presented at IBC’s 9th Annual Cell Line Development & Engineering Conference MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at IBC’s 9th Annual Cell Line Development & Engineering Confer...

BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the USC Minisymposium: Musculoskeletal Development and Repair conference at the Keck School of Medicine, the University of Southern California, on...

Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), supporting the development of novel human anti...

Oxygen Biotherapeutics financial update

NW Bio Phase III trial with DCVax-L for brain cancer commences at King's College Hospital

Northwest Biotherapeutics (NW Bio) has announced that the King's College Hospital in the UK commenced Phase III trial with DCVax-L for brain cancer.

NW Bio starts Phase III clinical trial with DCVax-L for brain cancer at King's College Hospital in UK

Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital...

Alethia gains US patent for cancer treatment methods

Alethia Biotherapeutics has gained US patent for methods of treating carcinomas with antibodies targeting the region of secreted clusterin (sCLU) responsible for promoting epithelial-to-mesenchymal transition (EMT).

Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), today announced that the NASDAQ Listing Qualifications Panel (the “Panel”) has granted the Company’s request for continued listing on The NASDAQ Capital Market pursuant to an extension through June 3, 2013 to evidence compliance with the minimum $1.00 bid price requirement and through July 31, 2013 to evid...

NW Bio Initiates Phase III DCVax®-L Brain Cancer Trial In Europe: King's College Hospital In The UK Is First Site To Open

BETHESDA, Md., May 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax®-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax®-L for brain cancer has been initiated at King's College Hospital in the UK. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084...

Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT

MONTREAL, QUEBEC -- (Marketwired) -- 05/16/13 -- Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, announced today that the Company has been granted United States Patent No. 8,426,562 covering methods of treating carcinomas with antibodies targeting the region of secreted clusterin (sCLU) responsible for promoti...

Conference Tackles Role of Biotherapeutic Drugs and Biosimilars, Harmonization of Regulatory Standards

Conference focuses on challenges in manufacturing biotherapeutics, evaluation and registration of biotherapeutic and biosimilar products, immunogenicity and safety monitoring, interchangeability, and pharmacovigilance.

SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market

FOSTER CITY, CA -- (Marketwired) -- 05/16/13 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company has entered into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd. granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Neucardin™, a novel, first-in-class therapeutic drug for th...

Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2013 UBS Global Healthcare Conference on Wednesday, May 22, 2013 at 8:00 a.m. ET at The Sheraton New York Hotel in New York City. A live audio webcast of the presentation will be available on the...

Jennerex Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types

SAN FRANCISCO, CA -- (Marketwired) -- 05/15/13 -- Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced the publication of data demonstrating the ability of its lead product-candidate, Pexa-Vec (JX-594, pexastimogene devacirepvec) to indu...

Jennerex Presents Pexa-Vec Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting

CHICAGO, IL -- (Marketwired) -- 05/15/13 -- Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that data relating to the company's lead product, Pexa-Vec (JX-594; pexastimogene devacirepvec), was featured in three separate abstracts du...

Bend Research Expands Analytical Sciences Capabilities and Capacity for Pharmaceutical Development

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced today that it has expanded its Good Manufacturing Practice (GMP) analytical capabilities and capacity for pharmaceutical development. Coupled with the company’s existing analytical-method development capabilities, Bend Research has...

Third Rock Ventures Expands and Strengthens Team

Third Rock Ventures, LLC, a venture capital firm focused on building healthcare companies, today announced that it has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation a...

Entera Health, Inc. Announces Presentations at Digestive Disease Week 2013

Entera Health, Inc. announces today three presentations will be given at Digestive Disease Week DDW® 2013, which is being held in Orlando, FL, Saturday, May 18 – Tuesday, May 21.   Rome IV Symposium May 17, 2013  ...

Jack Green Joins Verastem as Chief Financial Officer

Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of John “Jack” Green as Chief Financial Officer. Mr. Green was the former Chief Financial Officer of GTC Biotherapeutics and has held multiple senior finance roles in public and private biote...

Aegis Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment

SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,440,631, its second patent providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human...

Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union

SAN DIEGO and IRVINE, Calif., May 13, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today the acquisition of exclusive distribution rights from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation, to Cynviloq™ (marketed as Genexol-PM® in South Korea) in the 27 countries of European Union (EU). IGDRASOL had previously obt...